Abstract:The Wnt/β-catenin pathway is constitutively active and promotes multiple tumor processes, including breast cancer metastasis. However, the underlying mechanism by which the Wnt/β-catenin pathway is constitutively activated in breast cancer metastasis remains unclear. Inhibition of Wnt antagonists is important for Wnt/β-catenin signaling activation, and post-transcriptional regulation of these antagonists by microRNAs (miRNAs) might be a possible mechanism underlying signaling activation. Regulation of nuclear pre-mRNA domain-containing 1A (RPRD1A) is a known inhibitor of cell growth and Wnt/β-catenin signaling activity, but the function and regulatory mechanism of RPRD1A in breast cancer have not been clarified. The aim of this study was to understand how regulators of the Wnt/β-catenin pathway may play a role in the metastasis of this cancer. Methods: RPRD1A expression and its association with multiple clinicopathological characteristics was analyzed immunohistochemically in human breast cancer specimens. miR-454-3p expression was analyzed using real-time PCR. RPRD1A or miR-454-3p knockdown and overexpression were used to determine the underlying mechanism of their functions in breast cancer cells. Xenografted tumor model, 3D invasive culture, cell migration and invasion assays and sphere formation assay were used to determine the biofunction of RPRD1A and miR-454-3p in breast cancer. Electrophoretic mobility shift assay (EMSA), luciferase reporter assay, and RNA immunoprecipitation (RIP) were performed to study the regulation and underlying mechanisms of RPRD1A and miR-454-3p expression and their correlation with the Wnt/β-catenin pathway in breast cancer. Results: The Wnt/β-catenin signaling antagonist RPRD1A was downregulated and its upstream regulator miR-454-3p was amplified and overexpressed in metastatic breast cancer, and both were correlated with overall and relapse-free survival in breast cancer patients. The suppression by miR-454-3p on RPRD1A was found to activate Wnt/β-catenin signaling, thereby promoting metastasis. Simultaneously, three other negative regulators of the Wnt/β-catenin pathway, namely, AXIN2, dickkopf WNT signaling pathway inhibitor (DKK) 3 and secreted frizzled related protein (SFRP) 1, were also found to be targets of miR-454-3p and were involved in the signaling activation. miR-454-3p was found to be involved in early metastatic processes and to promote the stemness of breast cancer cells and early relapse under both in vitro and in vivo conditions. Conclusions: The findings indicate that miR-454-3p-mediated suppression of Wnt/β-catenin antagonist RPRD1A, as well as AXIN2, DKK3 and SFRP1, sustains the constitutive activation of Wnt/β-catenin signaling; thus, miR-454-3p and RPRD1A might be potential diagnostic and therapeutic targets for breast cancer metastasis.

Mir-214 Inhibits Epithelial-Mesenchymal Transition of Breast Cancer Cells Via Downregulation of RNF8.

Mir-145 Suppresses Breast Cancer Cell Migration by Targeting FSCN-1 and Inhibiting Epithelial-Mesenchymal Transition.

MiR-205 suppressed the malignant behaviors of breast cancer cells by targeting CLDN11 via modulation of the epithelial-to-mesenchymal transition

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

Mir-219A-5p Inhibits Breast Cancer Cell Migration and Epithelial-Mesenchymal Transition by Targeting Myocardin-Related Transcription Factor A.

Tumor-promoting Properties of Mir-8084 in Breast Cancer Through Enhancing Proliferation, Suppressing Apoptosis and Inducing Epithelial–mesenchymal Transition

MicroRNA-34a Inhibition of the TLR Signaling Pathway Via CXCL10 Suppresses Breast Cancer Cell Invasion and Migration.

MiR-454-3p-Mediated Wnt/β-catenin Signaling Antagonists Suppression Promotes Breast Cancer Metastasis

MiR-206 Suppresses Epithelial Mesenchymal Transition by Targeting TGF-β Signaling in Estrogen Receptor Positive Breast Cancer Cells

Mir-194 Suppresses Metastasis of Non-Small Cell Lung Cancer Through Regulating Expression of BMP1 and P27(kip1).

Regulation of Cancerous Progression and Epithelial-Mesenchymal Transition by Mir-34C-3p Via Modulation of MAP3K2 Signaling in Triple-Negative Breast Cancer Cells.

Mir-214-3p Inhibits Epithelial-to-mesenchymal Transition and Metastasis of Endometrial Cancer Cells by Targeting TWIST1

Mir-892b Silencing Activates Nf-Kappa B And Promotes Aggressiveness In Breast Cancer

Mir-340 and ZEB1 Negative Feedback Loop Regulates TGF-β- Mediated Breast Cancer Progression.

Mir-204 Regulates the Biological Behavior of Breast Cancer MCF-7 Cells by Directly Targeting FOXA1

Mir-598 Inhibits Metastasis in Colorectal Cancer by Suppressing JAG1/Notch2 Pathway Stimulating EMT

Down-Regulation of miR-194-5p for Predicting Metastasis in Breast Cancer Cells

Mir‑185‑5p Inhibits F‑actin Polymerization and Reverses Epithelial Mesenchymal Transition of Human Breast Cancer Cells by Modulating RAGE.

Mir-187 Inhibits the Growth of Cervical Cancer Cells by Targeting FGF9

Mir-494 Suppresses the Progression of Breast Cancer in Vitro by Targeting CXCR4 Through the Wnt/β-catenin Signaling Pathway.

Mir-34b Inhibits Breast Cancer Cell Epithelial-Mesenchymal Transition (Emt) And Invasion Via Targeting Glioma-Associated Oncogene Protein 1 (Gli1)